Estimating acceleration time point of respiratory decline in ALS patients: A novel metric.


Journal

Journal of the neurological sciences
ISSN: 1878-5883
Titre abrégé: J Neurol Sci
Pays: Netherlands
ID NLM: 0375403

Informations de publication

Date de publication:
15 Aug 2019
Historique:
received: 23 01 2019
revised: 19 04 2019
accepted: 27 05 2019
pubmed: 7 6 2019
medline: 9 9 2020
entrez: 7 6 2019
Statut: ppublish

Résumé

We aimed to derive and assess a novel metric for respiratory decline: the timing of acceleration of respiratory functional decline during the course of the disease in patients with amyotrophic lateral sclerosis (ALS). In this single-center retrospective study, we reviewed consecutive definite/probable ALS patients, diagnosed and followed up at our hospital. We recorded serial slow vital capacity (percentage of predicted slow vital capacity; %VC) since diagnosis for all patients. These serial %VC data were fitted with logistic function of the time since diagnosis, and 'acceleration point' was calculated as the week in which the second derivative of the fitted logistic function had the minimum value. We included 62 patients with ALS, whose serial %VC data had been recorded for a median of 8 times over a median of 94.3 weeks. The calculated acceleration time-point was the time-point at which the %VC is becoming 0.789 times of maximum %VC, and had a strong association with the period since diagnosis to the administration of nutritional/respiratory support (p < 0.001). Bulbar-type ALS or lower Body Mass Index at diagnosis, both are well-known ALS prognostic factors, were also associated with more rapid arrival of the acceleration time-point. We introduced the time-point of acceleration in the vital capacity decline during disease progression as a novel metric for ALS respiratory decline. Although we could not build a practically-available clinical model that directly predicts acceleration time-point due to the limited sample size, our metric may be used as one of the helpful indicators in the management during earlier disease course of ALS, such as to be careful for the potentially approaching acceleration time-point when the %VC is decreasing to approximately 0.789 times of initial %VC.

Identifiants

pubmed: 31170513
pii: S0022-510X(19)30247-3
doi: 10.1016/j.jns.2019.05.031
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

7-12

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Kenichiro Sato (K)

Department of Neurology, Graduate School of Medicine, University of Tokyo, Japan.

Atsushi Iwata (A)

Department of Neurology, Graduate School of Medicine, University of Tokyo, Japan. Electronic address: iwata-tky@umin.ac.jp.

Masanori Kurihara (M)

Department of Neurology, Graduate School of Medicine, University of Tokyo, Japan.

Yu Nagashima (Y)

Department of Neurology, Graduate School of Medicine, University of Tokyo, Japan.

Tatsuo Mano (T)

Department of Neurology, Graduate School of Medicine, University of Tokyo, Japan.

Tatsushi Toda (T)

Department of Neurology, Graduate School of Medicine, University of Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH